MET and non-small cell lung carcinoma: Herein, we used clinical routine technologies to determine the alteration status of 8 major driver genes, including the anaplastic lymphoma kinase (ALK), KRAS, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), BIM, PTEN, MET, IGF1R and ROS proto-oncogene 1 (ROS1) in advanced NSCLC patients.